Your browser doesn't support javascript.
loading
Indazole to 2-cyanoindole scaffold progression for mycobacterial lipoamide dehydrogenase inhibitors achieves extended target residence time and improved antibacterial activity.
Bryk, Ruslana; Sun, Shan; Ginn, John; Kochanczyk, Tomasz; Arango, Nancy; Jiang, Xiuju; Huggins, David J; Bean, James; Michino, Mayako; Baxt, Leigh; Liverton, Nigel; Meinke, Peter T.
Afiliação
  • Bryk R; Weill Cornell Medicine, Microbiology and Immunology, 413 East 69 Street, BRB-11, 10065-4805, New York, UNITED STATES OF AMERICA.
  • Sun S; Sanders Tri-Institutional Therapeutics Discovery Institute, Computational Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.
  • Ginn J; Sanders Tri-Institutional Therapeutics Discovery Institute, Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.
  • Kochanczyk T; Sloan-Kettering Institute, Structural Biology, 1275 York Avenue, 10065, New York, UNITED STATES.
  • Arango N; Sloan-Kettering Institute, Structural Biology, 1275 York Avenue, 10065, New York, UNITED STATES.
  • Jiang X; Weill Cornell Medicine, Microbiology and Immunology, 413 East 69 Street, BRB-11, 10065-4805, New York, UNITED STATES.
  • Huggins DJ; Sanders Tri-Institutional Therapeutics Discovery Institute, Computational Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.
  • Bean J; Sloan-Kettering Institute, Immunology, 1275 York Avenue, 10065, New York, UNITED STATES.
  • Michino M; Sanders Tri-Institutional Therapeutics Discovery Institute, Computational Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.
  • Baxt L; Sanders Tri-Institutional Therapeutics Discovery Institute, Biology, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.
  • Liverton N; Sanders Tri-Institutional Therapeutics Discovery Institute, Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.
  • Meinke PT; Sanders Tri-Institutional Therapeutics Discovery Institute, Chemistry, Bronk Laboratory, 1230 York Avenue, Box 122, 10065, New York, UNITED STATES.
Angew Chem Int Ed Engl ; : e202407276, 2024 Jul 12.
Article em En | MEDLINE | ID: mdl-38997232
ABSTRACT
Tuberculosis remains a leading cause of death from a single infection worldwide. Drug resistance to existing and even new antimycobacterials calls for research into novel targets and unexplored mechanisms of action. Recently we reported on the development of tight-binding inhibitors of Mycobacterium tuberculosis (Mtb) lipoamide dehydrogenase (Lpd), which selectively inhibit the bacterial but not the human enzyme based on a differential modality of inhibitor interaction with these targets. Here we report on the striking improvement in inhibitor residence time on the Mtb enzyme associated with scaffold progression from an indazole to 2-cyanoindole. Cryo-EM of Lpd with the bound 2-cyanoindole inhibitor 19 confirmed displacement of the buried water molecule deep in the binding channel with a cyano group. The ensuing hours-long  improvement in on-target residence time is associated with enhanced antibacterial activity in axenic culture and in primary mouse macrophages. Resistance to 2-cyanoindole inhibitors involves mutations within the inhibitor binding site that have little effect on inhibitor affinity but change the modality of inhibitor-target interaction, resulting in fast dissociation from Lpd. These findings underscore that on-target residence time is a major determinant of antibacterial activity and in vivo efficacy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article